stockrowHarmony Biosciences Holdings, Inc.
HRMY Healthcare Biotechnology
Harmony Biosciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $868.5 million, up 21.5% from fiscal 2024.
- Revenue
- +12.3%
- EPS
- −6.24%
- Free cash flow
- −29.4%
- Total debt
- −11.5%
Quarter to September 2026, against a year earlier
Follow HRMY
Alert me
Harmony Biosciences Holdings, Inc. (HRMY) P/E ratio
As of 6 November 2026, Harmony Biosciences Holdings, Inc. (HRMY) trades at a P/E ratio of 10.7×. Over the past ten years it has ranged from 0.0× (June 2021) to 209× (December 2021); the current reading is higher than 26% of that period. That is in line with the Biotechnology industry median of 10.6× and below the Healthcare sector median of 24.5×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 13.6× | 1.23% |
| FY2024 | 13.4× | (5.70%) |
| FY2023 | 14.3× | (17.64%) |
| FY2022 | 17.3× | (75.65%) |
| FY2021 | 71.1× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2026 | 12.8× | 9.75% |
| Jun 2026 | 11.6× | 4.66% |
| Mar 2026 | 11.1× | (18.32%) |
| Dec 2025 | 13.6× | 59.48% |
| 23 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MESO Mesoblast Limited compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| FTRE Fortrea Holdings Inc. compare | n/m |
| VIR Vir Biotechnology, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | n/m |
| HRMY Harmony Biosciences Holdings, Inc. | 10.7× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)